Publications by authors named "Peter Rossing"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

457,472

Total Likes

10,201

Extended Reach

11,314,469

Social Features

2,156
F
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
Rajiv Agarwal, Jennifer B Green, Hiddo J L Heerspink, Johannes F E Mann, Janet B McGill, Amy K Mottl, Julio Rosenstock, Peter Rossing, Muthiah Vaduganathan, Meike Brinker

N Engl J Med· August 2025

Videos about Article: user user

2 10 204 5 86

View All Article and Social Media Activity
E
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.
Richard E Pratley, Katherine R Tuttle, Peter Rossing, Søren Rasmussen, Vlado Perkovic, Olav Wendelboe Nielsen, Johannes F E Mann, Richard J MacIsaac, Mikhail N Kosiborod, Zdravko Kamenov

J Am Coll Cardiol· October 2024

Videos about Article: user user

2 58 5

View All Article and Social Media Activity
E
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Vlado Perkovic, Katherine R Tuttle, Peter Rossing, Kenneth W Mahaffey, Johannes F E Mann, George Bakris, Florian M M Baeres, Thomas Idorn, Heidrun Bosch-Traberg, Nanna Leonora Lausvig

N Engl J Med· July 2024

Videos about Article: user user user 7

10 4 10 259 14 316

View All Article and Social Media Activity
M
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, Vanita R Aroda, Billy S Collins, Robert A Gabbay, Jennifer Green, Nisa M Maruthur, Sylvia E Rosas, Stefano Del Prato, Chantal Mathieu, Geltrude Mingrone

Diabetes Care· November 2022

Videos about Article: user user

2 2 12 328 4 53

View All Article and Social Media Activity
C
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Bertram Pitt, Gerasimos Filippatos, Rajiv Agarwal, Stefan D Anker, George L Bakris, Peter Rossing, Amer Joseph, Peter Kolkhof, Christina Nowack, Patrick Schloemer

December 2021

Videos about Article: user user user 1

4 1 8 304 6 62

View All Article and Social Media Activity
A
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
David C Wheeler, Robert D Toto, Bergur V Stefánsson, Niels Jongs, Glenn M Chertow, Tom Greene, Fan Fan Hou, John J V McMurray, Roberto Pecoits-Filho, Ricardo Correa-Rotter

July 2021

Videos about Article: user user

2 4 200 3 15

View All Article and Social Media Activity
F
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Gerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Patrick Schloemer, Ingo Tornus, Amer Joseph

February 2021

Videos about Article: user user

2 2 57 2 17 2

View All Article and Social Media Activity
E
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph

N Engl J Med· December 2020

Videos about Article: user user user 1

4 3 8 286 8 104

View All Article and Social Media Activity
D
Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing

October 2020

Videos about Article: user user user 5

8 3 17 271 9 68 2

View All Article and Social Media Activity
2
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies

Diabetologia· February 2020

Videos about Article: user user user 2

5 8 125 6

View All Article and Social Media Activity
E
Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function.
Shigehiro Katayama, Stefan D Anker, Dalong Zhu, SungGyun Kim, Ming-Ju Wu, Peter Rossing

J Diabetes Complications· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dickkopf 3 in Urine: A Help for Prioritizing Management of Kidney Disease in Type 2 Diabetes.
Peter Rossing

Diabetes· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial.
Muthiah Vaduganathan, Jennifer B Green, Hiddo J L Heerspink, Sung Gyun Kim, Johannes F E Mann, Peter Rossing

Nephrol Dial Transplant· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infective endocarditis and relationship with diabetes mellitus - Patient characteristics, microbial etiology and mortality.
Andreas Dalsgaard Jensen, Lauge Østergaard, Peter Laursen Graversen, Katra Hadji-Turdeghal, Jeppe K Petersen, Peter Rossing

Infection· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study protocol for the investigator-initiated Danish pragmatic randomised STENO INTEN-CT trial: does screening and intervention for subclinical coronary artery disease in type 2 diabetes reduce cardiovascular events?
Kristian Løkke Funck, Britt Borregaard, Kenneth Egstrup, Eskild Klausen Fredslund, Tine Willum Hansen, Peter Rossing

BMJ Open· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW.
Peter Rossing, Morten Lindhardt, Christian Klyver Tikkanen, Jyothi Menon, Juliette Cattin

Cardiovasc Diabetol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD.
Isabella A Gashaw, Katherine R Tuttle, Manuel Monroy Kuhn, Sina Pleiner, Denis Delic, Peter Rossing

Eur J Endocrinol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials.
John W Ostrominski, Josephine Harrington, Brian L Claggett, Gerasimos Filippatos, Akshay S Desai, Peter Rossing

J Am Coll Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial).
Rajiv Agarwal, Jennifer B Green, Hiddo J L Heerspink, Johannes F E Mann, Janet B McGill, Peter Rossing

Diabetes Care· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to the letter to the editor entitled "Semaglutide and kidney function: direct kidney protection or an artifact?".
Vlado Perkovic, Katherine R Tuttle, Peter Rossing, Johannes F E Mann, Thomas Idorn

Kidney Int· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Dapagliflozin on Progression of CKD According to Different Rates of Pretrial eGFR Loss.
Hiddo J L Heerspink, Glenn M Chertow, Peter Rossing, Ricardo Correa-Rotter, C David Sjöström

Clin J Am Soc Nephrol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac Effects of Dapagliflozin in People with Chronic Kidney Disease.
Katja Vu Bartholdy, Niklas Dyrby Johansen, Kristoffer Grundtvig Skaarup, Daniel Modin, Nino Landler, Peter Rossing

NEJM Evid· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.
Amy Mottl, Charlie Scott, Jennifer B Green, Hiddo J L Heerspink, Johannes F E Mann, Peter Rossing

J Am Soc Nephrol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease.
Denis Delic, Isabella Gashaw, Ileana Duran-Fernandez, Lisa Cronin, Sibylle J Hauske, Peter Rossing

Int J Mol Sci· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timing of Cardiovascular and Kidney Benefits With Finerenone in Heart Failure and Chronic Kidney Disease With Type 2 Diabetes.
John W Ostrominski, Brendon L Neuen, Brian L Claggett, Gerasimos Filippatos, Akshay S Desai, Peter Rossing

J Am Coll Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Joslin Kidney Panel of Circulating Proteins: A Tool for ESKD Risk Discrimination and Individualized Diabetic Kidney Disease Treatment.
Andrzej S Krolewski, Jani K Haukka, Zaipul I Md Dom, Viktor R Curovic, Chunyi Wu, Peter Rossing

Clin J Am Soc Nephrol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocol for the FibroCAN study: a randomised controlled trial of finerenone treatment for early-stage cardiovascular autonomic neuropathy in type 2 diabetes.
Maria Bitsch Poulsen, Tina Okdahl, Jens Hove Buciek, Asbjørn Mohr Drewes, Pall Karlsson, Peter Rossing

BMJ Open· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Busting a Myth: Sodium-Glucose Cotransporter-2 Inhibitors do not Cause Postoperative Acute Kidney Injury.
Peter Rossing

Kidney Int Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. Reply.
Rajiv Agarwal, Peter Rossing, Johannes F E Mann

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current advances in diabetic neuropathy: Proteins as therapeutic targets.
Gurjeet Kaur, Salaha Osman Ali, Alberto Santos, Tina Okdahl, Anne-Marie Wegeberg, Peter Rossing

iScience· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Susan L Furth, Helen M Colhoun, Mehmet Kanbay, Aleksandra Kukla, Lee-Ling Lim, Peter Rossing

Kidney Int· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Finerenone on Morbidity and Mortality in CKD.
John W Ostrominski, Gerasimos Filippatos, Brian L Claggett, Zi Michael Miao, Akshay S Desai, Peter Rossing

J Am Soc Nephrol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE.
Rajiv Agarwal, Jennifer B Green, Hiddo J L Heerspink, Johannes F E Mann, Janet B McGill, Peter Rossing

Clin J Am Soc Nephrol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations.
Hiddo J L Heerspink, Rajiv Agarwal, Antonio J Amor, Jesper N Bech, David Z I Cherney, Peter Rossing

Nephrol Dial Transplant· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left ventricular ejection fraction reserve and its association with myocardial perfusion, coronary calcification, and strain in type 2 diabetes without overt cardiovascular disease.
Adam Chebli, Ida K B Rasmussen, Anne-Cathrine Skriver-Møller, Philip Hasbak, Martin B Blond, Peter Rossing

Cardiovasc Diabetol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis